6月4日 - ** 药物开发商Sagimet Biosciences SGMT.O股价盘前上涨52%至5.53美元
** SGMT称其口服痤疮药物denifanstat在中国合作伙伴Ascletis1672.HK进行的后期试验中达到了主要目标 (link)。
** 地尼凡司他的治疗成功率为33.2%，安慰剂为14.6%。
** 德尼凡司他通过一种新的作用机制抑制皮脂的产生，皮脂是导致痤疮的关键因素。
** 该药可使痤疮皮损总数减少57.4%，而安慰剂仅为35.4%。
** Ascletis计划向中国监管机构提交denifanstat的审批申请
** 截至上一交易日收盘，股价累计下跌19.3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.